🔎 Trials Near Me

Utama › Atrofi Geografik › Arizona

Kajian klinikal Atrofi Geografik di Arizona

5 kajian untuk Atrofi Geografik sedang mencari peserta di lokasi di Arizona.

Bandar di Arizona

Teks kajian rasmi (Bahasa Inggeris)

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  • Retina Associates Southwest PC, Tucson
Mengambil pesertaFasa 2/3
Umur 60 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT06635148

A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

  • Associated Retina Consultants - PHX, Gilbert
  • Associated Retina Consultants, Phoenix
Mengambil pesertaFasa 1/2
Umur 55 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07029945

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

  • Associated Retina Consultants - Peoria- Site Number : 8400011, Peoria
  • Retina Macula Institute of Arizona- Site Number : 8400028, Scottsdale
Mengambil pesertaFasa 1/2
Umur 60 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07215234

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  • Barnet Dulaney Perkins Eye Center-Ophthamalogy, Chandler
  • Barnet Dulaney Perkins Eye Center, Phoenix
  • Associated Retina Consultants, Phoenix
  • dan 3 lagi
Mengambil pesertaFasa 3
Umur 50 hingga 85 · Semua jantina · Dikemas kini 18 Sep 2026 · NCT06541704

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

  • Associated Retina Consultants, Gilbert
  • Associated Retina Consultants, Phoenix
Mengambil pesertaFasa 2
Umur 55 ke atas · Semua jantina · Dikemas kini 10 Sep 2026 · NCT06659445

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.